Procter & Gamble: Barclays Maintains Equal-Weight, PT Down to $153
PorAinvest
miércoles, 1 de octubre de 2025, 11:38 am ET1 min de lectura
BCS--
The downgrade comes amidst a period of significant changes in Procter & Gamble's portfolio. The company recently reported its quarterly earnings, beating analysts' expectations with earnings per share (EPS) of $1.48, up from $1.40 a year ago. The company also increased its dividend payout ratio to 64.82%, indicating strong financial health.
Barclays' downgrade follows a recent trend of analysts adjusting their price targets for Procter & Gamble. Evercore ISI, for instance, reissued an "In-line" rating and set a $170.00 price objective, while BNP Paribas Exane cut their price target to $172.00. Despite these changes, Procter & Gamble remains one of the most highly-rated stocks among analysts, with an average rating of "Moderate Buy" and an average price target of $173.68.
The company's strong fundamentals and consistent dividend payouts make it an attractive investment for long-term investors. However, the recent downgrade by Barclays suggests that investors should closely monitor the company's performance and adjust their expectations accordingly.
PG--
Procter & Gamble: Barclays Maintains Equal-Weight, PT Down to $153
Barclays has downgraded Procter & Gamble (NYSE:PG) to an "Equal Weight" rating from "Overweight," while lowering its price target to $153 from $164. The brokerage cited several factors for the downgrade, including rising competition and limited growth prospects. However, Barclays maintained a "Buy" rating for the company, suggesting that while the stock may not be as attractive as before, it still offers a good investment opportunity.The downgrade comes amidst a period of significant changes in Procter & Gamble's portfolio. The company recently reported its quarterly earnings, beating analysts' expectations with earnings per share (EPS) of $1.48, up from $1.40 a year ago. The company also increased its dividend payout ratio to 64.82%, indicating strong financial health.
Barclays' downgrade follows a recent trend of analysts adjusting their price targets for Procter & Gamble. Evercore ISI, for instance, reissued an "In-line" rating and set a $170.00 price objective, while BNP Paribas Exane cut their price target to $172.00. Despite these changes, Procter & Gamble remains one of the most highly-rated stocks among analysts, with an average rating of "Moderate Buy" and an average price target of $173.68.
The company's strong fundamentals and consistent dividend payouts make it an attractive investment for long-term investors. However, the recent downgrade by Barclays suggests that investors should closely monitor the company's performance and adjust their expectations accordingly.

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema



Comentarios
Aún no hay comentarios